Viral pneumonia

Current Opinion in Infectious Diseases

Volumn 22, Issue 2, 2009, Pages 143-147

  Marcos, Maria Angeles ^a   Esperatti, Mariano ^a   Torres, Antoni ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Antiviral drugs; Infection; Pneumonia; Virus

Indexed keywords

AMANTADINE; CEFOTAXIME; CEFTRIAXONE; NUCLEIC ACID; OSELTAMIVIR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; TRIPLE VACCINE; ZANAMIVIR;

ADENOVIRUS; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; HUMAN; INFLUENZA VIRUS A; NUCLEIC ACID AMPLIFICATION; PARAINFLUENZA VIRUS 1; PARAINFLUENZA VIRUS 2; PARAINFLUENZA VIRUS 3; POPULATION; PREDICTION; PROGNOSIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SCORING SYSTEM; VIRUS PNEUMONIA;

ANTIVIRAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; HUMANS; INCIDENCE; PNEUMONIA, VIRAL; VIRUSES;

EID: 63849320741     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328328cf65     Document Type: Article

References (37)

1. Mathers C, Bernard C, Moesgaard Iburg K, et al. WHO. Global burden of disease in 2002: data sources, methods and results, http://www.who.int/ healthinfo/paper54.pdf. [Accessed 10 November 2008].
2. Marcos MA, Camps M, Pumarola T, et al. The role of viruses in the aetiology of community-acquired pneumonia in adults. Antivir Ther 2006; 11:351- 359.
3. Jennings LC, Anderson TP, Beynon KA. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax 2008; 63:42-48.
4. Johnstone J, Majumdar SR, Fox JD, Marrie TJ. Viral infection in adults hospitalized with community acquired pneumonia: prevalence, pathogens and presentation. Chest 2008; 134:1141-1148.
5. Schoub B, Martin D. Influenza pandemic preparedness. WHO; 2006. http://www.who.int/csr/disease/influenza/southafricaplan.pdf. [Accessed November 2008].
6. Falsey A, Walsh E. Viral pneumonia in older adults. Clin Infect Dis 2006; 42:518-524.
7. Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352:1749-1759.
8. Hayden FG. Rhinovirus and the lower respiratory tract. Rev Med Virol 2004; 14:17-31.
9. Kupfer B, Simon A, Jonassen CM, et al. Two cases of severe obstructive pneumonia associated with an HKU1 -like coronavirus. Eur J Med Res 2007; 12:134-138.
10. Gerna G, Campanini G, Rovida F, et al. Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients. J Med Virol 2006; 78:938-949.
11. Longtin J, Bastien M, Gilca R, et al. Human bocavirus infections in hospitalized children and adults. Emerg Infect Dis 2008; 14:217-221.
12. Templeton KE, Scheltinga SA, Van den Eeden WC, et al. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005; 41:345-351.
13. Halm EA, Teirstein AS. Management of community-acquired pneumonia. N Engl J Med 2002; 34:2039-2045.
14. File TM. Community-acquired pneumonia. Lancet 2003; 362:1991 -2001.
15. Johnstone J, Majumdar RM, Fox JD, Marrie TJ. Human metapneumovirus pneumonia in adults: results of a prospective study. Clin Infect Dis 2008; 46:571-574.
16. Rovida F, Percivalle E, Zavattoni M, et al. Monoclonal antibodies versus reverse transcription-PCR for detection of respiratory viruses in a patient population with respiratory tract infections admitted to hospital. J Med Virol 2005; 75:336-347.
17. Fujimoto T, Okafuji T, Okafuji T, et al. Evaluation of a beside immuno-chromatographic test for detection of adenovirus in respiratory samples, by comparison to virus isolation, PCR, and real-time PCR. J Clin Microbiol 2004; 42:5489-5492.
18. Aldous WK, Gerber K, Taggart EW, et al. A comparison of Binax NOW to viral culture and direct fluorescent assay testing for respiratory syncytial virus. Diagn Microbiol Infect Dis 2004; 49:265-268.
19. Rahman M, Vandermause MF, Kieke BA, Belongia EA. Performance of Binax NOW Flu A and B and direct fluorescent assay in comparison with a composite of viral culture or reverse transcription polymerase chain reaction for detection of influenza infection during the 2006 to 2007 season. Diag Microbiol Infect Dis 2008; 62:162-166.
20. Vikerfors T, Grandien M, Johansson M, Pettersson CA. Detection of an immunoglobulin M response in the elderly for early diagnosis of respiratory syncytial virus infection. J Clin Microbiol 1988; 26:808-811.
21. De Roux A, Marcos MA, Garcia E, et al. Viral community-acquired pneumonia in nonimmunocompromised adults. Chest 2004; 125:1343-1351.
22. Mahony JB. Detection of respiratory viruses by molecular methods. Clin Microbiol Rev 2008; 21:716-747.
23. Brittain-Long R, Nord S, Olofsson S, et al. Multiplex real-time PCR for detection of respiratory tract infections. J Clin Virol 2008; 41:53-56.
24. Lam WY, Yeung ACM, Tang JW, et al. Rapid multiplex nested PCR for detection of respiratory viruses. J Clin Microbiol 2007; 45:3631 -3640.
25. Percivalle E, Rovida F, Piralla A, et al. Rapid typing, subtyping and RNA quantification of influenza virus type A strains in respiratory secretions. New Microbiol 2008; 31:319-327.
26. Mahony J, Chong S, Merante F, et al. Development of a respiratory virus panel test for the detection of twenty human respiratory viruses by using multiplex PCR and a fluid microbead-based assay. J Clin Microbiol 2007; 45:2965- 2970.
27. Pabbaraju K, Tokaryk KL, Wong S, et al. Comparison of the Luminex xTAG respiratory viral panel with in-house nucleic acid amplification tests for diagnosis of respiratory virus infections. J Clin Microbiol 2008; 46:3056- 3062.
28. Brunstein JD, Cline CL, McKinney S, et al. Evidence from multiplex molecular assays for complex multipathogen interactions in acute respiratory infections. J Clin Microbiol 2008; 46:97-102.
29. Simmons C, Farrar J. Insights into inflammation and influenza. N Engl J Med 2008;359:1621-1623.
30. Abed Y, Boivin G. Treatment of respiratory virus infections. Antivir Res 2006; 70:1-16.
31. Monto AS. The role of antivirals in the control of influenza. Vaccine 2003; 21:1796-1800.
32. Jefferson T, Demicheli V, Rivetti D, et al. Antivirals for influenza in healthy adults: systematic review. Lancet 2006; 367:303-313.
33. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353:1363-1373.
34. National Institute for Clinical Excellence. Guidance on the use of zanamivir, oseltamivir and amantadine for the treatment of influenza; 2003. http://www.nice.org.uk:80/nicemedia/pdf/58-Flu-fullguidance.pdf.
35. Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003; 163:1667-1672.
36. Roberts NA. Treatment of influenza with neuraminidase inhibitors virological implications. Philos Trans R Soc Lond B Biol Sci 2001; 353:1895-1897.
37. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl 2):S27-S72.